Opinion

Video

Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment advances, while highlighting expanding applications in solid tumors, autoimmune disorders, and infectious diseases as promising growth areas for this therapeutic modality.

Video content above is prompted by the following:

  • What are the most significant recent approvals for bispecific antibodies in oncology?
  • What therapeutic areas are seeing growth in bispecific antibody applications?
Related Videos
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
3 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo